Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

PAVmed Inc. Common Stock

PAVM

PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $1.43 – $1.83
Volume 32,046
Market cap $14M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$13.99M
Price / earnings
—
Price / book
0.4×
Price / sales
124.94×
EV / sales
225.97×
EV / EBITDA
-1.07×

Profitability

Earnings per share
-$2.58
Return on assets
-51.29%
Return on equity
-58.85%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.43×
Current ratio
1.19×
Quick ratio
1.19×
Cash ratio
0.93×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$7.78M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PAVM, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$33K$22K$52K$5K$6K$8K$10K$996K
Cost of revenue$122K$97K$85K$55K$41K$36K$48K$1.38M
Gross profit-$89K-$75K-$33K-$50K-$35K-$28K-$38K-$385K
Selling, general and administrative$1.72M$6.57M$4.94M$3.71M$740K$4.63M$4.34M$9.57M
Research and development$2.07M$1.39M$1.83M$1.09M$790K$787K$807K$1.54M
Total operating expenses$3.78M$7.96M$6.77M$4.79M$1.53M$5.42M$5.15M$11.19M
Operating income-$3.87M-$8.04M-$6.8M-$4.84M-$1.57M-$5.45M-$5.19M-$11.58M
Interest expense-$2K-$3K-$5K-$8K-$4K-$4K-$7K-$12K
Income before taxes-$6.6M-$1.06M-$2.76M-$6.01M-$12.32M$18.62M$1.14M$60.71M
Income taxes$0$0$0$0$0$0$0$0
Net income-$6.6M-$1.06M-$2.76M-$6.01M-$12.32M$18.62M$1.14M$60.71M
Net income attributable to common shareholders-$5.48M-$6.99M-$1.83M-$6.33M-$13.31M$17.7M$1.35M$64.32M
EBITDA-$3.85M-$8.02M-$6.79M-$4.93M-$1.54M-$5.4M-$5.12M-$11.5M
Basic earnings per share-$0.87-$4.42-$2.04-$8.70-$22.08$38.26$3.73$192.90
Diluted earnings per share-$0.87-$4.42—-$8.70-$22.08$10.10$0.20$43.20

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

Lucid Diagnostics to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 26, 2026

Lucid Diagnostics Inc. (NASDAQ:LUCD), a cancer prevention medical diagnostics company and subsidiary of PAVmed Inc., announced it will host a business update conference call and webcast on March 26, 2026, at 8:30 AM ET. CEO Lishan Aklog will provide a business update and discuss operations and growth strategy, while CFO Dennis McGrath will discuss fourth quarter 2025 financial results.

Benzinga

PAVmed Announces Reverse Stock Split

PAVmed Inc. announced a 1-for-30 reverse stock split effective January 2, 2026, to comply with Nasdaq's $1.00 minimum bid price requirement. The split was approved by stockholders on December 5, 2025, and authorized shares will be reduced from 250 million to 25 million. The company's stock will continue trading under symbol PAVM on Nasdaq Capital Market.

Benzinga

Lucid Diagnostics Announces Proposed Public Offering of Common Stock

Lucid Diagnostics, a cancer prevention medical diagnostics company, announced plans for a public stock offering to support working capital and general corporate purposes, with Canaccord Genuity LLC and BTIG, LLC acting as joint bookrunners.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jan 2, 20261-for-30reverse split
Dec 7, 20231-for-15reverse split